^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AB248

    i
    Other names: AB248
    Associations

    News

    Trials
    Company:
    Asher Biotherap
    Drug class:
    IL-2 stimulant, CD8 T-cell agonist
    Related drugs:
    Associations

    News

    Trials
    6ms
    KEYNOTE-E29: A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=462, Recruiting, Asher Biotherapeutics, Inc. | N=262 --> 462 | Trial completion date: Oct 2025 --> May 2027 | Trial primary completion date: Jun 2025 --> Aug 2026
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • AB248
    8ms
    IL-2 targeted to CD8+ T cells promotes robust effector T cell responses and potent antitumor immunity. (PubMed, Cancer Discov)
    Efficacy was associated with expansion and phenotypic enhancement of tumor-infiltrating CD8+ T cells, including the emergence of a "better effector" population. These data support the potential utility of AB248 in clinical settings.
    Journal
    |
    CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
    |
    AB248
    11ms
    KEYNOTE-E29: A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=262, Recruiting, Asher Biotherapeutics, Inc.
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • AB248
    almost1year
    KEYNOTE-E29: A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=262, Recruiting, Asher Biotherapeutics, Inc. | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • AB248
    over1year
    An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors (AACR 2023)
    Adverse events will be assessed by CTCAE v5.0. The study is currently open for enrollment in the dose escalation phase at multiple sites in the US.
    Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
    |
    Keytruda (pembrolizumab) • AB248
    almost2years
    A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=262, Recruiting, Asher Biotherapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    Keytruda (pembrolizumab) • AB248
    almost2years
    A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=262, Not yet recruiting, Asher Biotherapeutics, Inc.
    New P1 trial • Combination therapy • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    Keytruda (pembrolizumab) • AB248